Sign In
27 Sep 2011 10:38
For immediate release | 27 September 2011 |
ABCAM PLC
("Abcam" or "the Company")
PDMR Dealings: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, was today notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to the benefit of certain of its PDMRs in line with their commitment to participate in the SIP on a monthly basis:
Name | Partnership Shares purchased on 26 September 2011 at 349.318 pence per share | Matching Shares awarded on 26 September 2011 at 349.318 pence per share |
Mark Bushfield | 36 | 36 |
Philippe Cotrel | 36 | 36 |
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded.
No consideration was paid by the above grantees for the award of the Matching Shares and no consideration is due on the release of these shares.
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 325 staff across its six operating companies.
Abcam now has an online catalogue of over 77,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.
Follow the stocks
